

PALATIN TECHNOLOGIES INC  
Form 8-K  
November 14, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): November 14, 2012

**Palatin Technologies, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**                      **001-15543**    **95-4078884**  
(State or other jurisdiction (Commission (IRS employer  
of incorporation)              File Number) identification number)

**4B Cedar Brook Drive, Cranbury, NJ 08512**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(609) 495-2200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On November 14, 2012, we issued a press release including results for our first quarter ended September 30, 2012, and announcing a teleconference and webcast to be held November 14, 2012 at 11:00 a.m. Eastern Time, which will include a discussion of positive top-line results, including the achievement of statistical significance for the primary endpoint and key secondary endpoints, in our Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction. We have attached a copy of the press release as an exhibit to this report.

The information in this Item 2.02 and the corresponding information in the attached Exhibit 99 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and the corresponding information in the attached Exhibit 99 shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

99Press Release dated November 14, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PALATIN TECHNOLOGIES, INC.

Edgar Filing: PALATIN TECHNOLOGIES INC - Form 8-K

Date: November 14, 2012 By: /s/ Stephen T. Wills  
Stephen T. Wills, CPA, MST

Executive Vice President, Chief Financial Officer and Chief Operating Officer

**EXHIBIT INDEX**

99 Press Release dated November 14, 2012